ADX-038 Dose Level 1

Phase 2

AADARx Pharmaceuticals, Inc.

ADX-038 Dose Level 1 is one of 6 therapeutic programs targeting IgAN. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

IganRecruiting

IganPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Igan

#DrugCompanyPhaseTrials

Ultomiris

AstraZeneca

Phase 3

1 2

Nubeqa

Bayer

Phase 2

1 3

TRUTAKNA

VVera Therapeutics, Inc.

Phase 2

1 4

ADX-038

AADARx Pharmaceuticals, Inc.

Phase 2

1 5

ADX-038 Dose Level 1

AADARx Pharmaceuticals, Inc.

Phase 2

1 6

Propolis

IIndonesia University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Igan

NCT06989359

Clinical

Trials by Indication[1]

IgAN1 trial

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

Recruiting·AADARx Pharmaceuticals, Inc.·Phase 2·NCT06989359·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ADX-038 Dose Level 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ADX-038 Dose Level 1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — ADARx Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AADARx Pharmaceuticals, Inc.

ADX-038 Dose Level 1

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

IgAN1 trial

References

Drug Info

Quick Facts

Related News